This paper describes a nano-plasmonic SERS-based serum fingerprinting method aimed at detecting Parkinson's disease signatures and monitoring therapeutic response noninvasively.

If validated, a sensitive serum SERS fingerprint could serve as a minimally invasive biomarker platform to track disease progression and treatment effects, improving clinical trial readouts and patient monitoring despite lacking direct mechanistic or therapeutic interventions.